183C91

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
012319972017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
BACKGROUND AND OBJECTIVE Oral zolmitriptan is highly effective in the acute treatment of migraine. However, nausea and vomiting… (More)
Is this relevant?
2002
2002
The objective of this study was to investigate the pharmacokinetics, dose proportionality, and tolerability of a range of single… (More)
Is this relevant?
2002
2002
Abstract Background. Zolmitriptan is a 5HT1B/1D receptor agonist effective in the acute treatment of migraine. Clinical trials in… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2002
2002
Two preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray were conducted, each involving 12… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
5-Hydroxytryptamine (5-HT) can produce both vasoconstrictor and vasorelaxant effects in human coronary arteries and the response… (More)
Is this relevant?
1998
1998
AIMS Zolmitriptan (Zomig (formerly 311C90)) is a novel 5-HT1B/1D receptor agonist developed for the acute oral treatment of… (More)
Is this relevant?
1998
1998
Two studies were conducted in healthy volunteers to evaluate the effects of rifampicin and cimetidine on the pharmacokinetics of… (More)
Is this relevant?
1997
1997
311C90 ("Zomig", zolmitriptan), is a novel and selective, centrally and peripherally acting 5 HT1B/1D receptor agonist in… (More)
Is this relevant?
1997
1997
Objective: This study investigated potential pharmacokinetic or pharmacodynamic interactions between the novel anti-migraine… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
Review
1997
Review
1997
Seven randomized studies in healthy volunteers have investigated interactions between zolmitriptan (Zomig, formerly 311C90), a… (More)
Is this relevant?